WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1994027637) MONOCLONAL ANTI-IDIOTYPIC ANTI-CA125 ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1994/027637    International Application No.:    PCT/EP1994/001719
Publication Date: 08.12.1994 International Filing Date: 26.05.1994
Chapter 2 Demand Filed:    20.12.1994    
IPC:
A61K 38/00 (2006.01), C07K 16/42 (2006.01), G01N 33/574 (2006.01), G01N 33/68 (2006.01)
Applicants: WAGNER, Uwe [DE/DE]; (DE).
SCHLEBUSCH, Harald [DE/DE]; (DE)
Inventors: WAGNER, Uwe; (DE).
SCHLEBUSCH, Harald; (DE)
Agent: VOSSIUS & PARTNER; P.O. Box 86 07 67, D-81634 Munich (DE)
Priority Data:
93108583.1 27.05.1993 EP
Title (EN) MONOCLONAL ANTI-IDIOTYPIC ANTI-CA125 ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
(FR) ANTICORPS MONOCLONAUX ANTI-CA125 ET ANTIIDIOTYPIQUES, ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
Abstract: front page image
(EN)Disclosed is an anti-idiotypic antibody which reacts with an anti-CA125 antibody and competes with CA125 in its binding to said anti-CA125 antibody. Furthermore, fragments of said anti-idiotypic antibody are disclosed which have essentially the same binding specificity. Additionally, the invention relates to cell lines, particularly to hybridoma 3D5 (DSM ACC2120), producing said anti-idiotypic antibodies. Also disclosed are pharmaceutical compositions containing said anti-idiotypic antibodies and specific uses of these antibodies.
(FR)Anticorps antiidiotypiques réagissant avec un anticorps anti-CA125 et entrant en compétition avec CA125 pour la liaison audit anticorps anti-CA125. L'invention se rapporte en outre à des fragments de cet anticorps antiidiotypique qui présentent la même spécificité de liaison, ainsi qu'à des lignées cellulaires, en particulier l'hybridome 3D5 (DSM ACC2120), qui produisent ces anticorps antiidiotypiques. L'invention se rapporte également à des compositions pharmaceutiques contenant de tels anticorps antiidiotypiques et à leurs utilisations spécifiques.
Designated States: AM, AU, CA, JP, TM, US.
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: English (EN)
Filing Language: English (EN)